Jeffrey Ha @jeffreyha.bsky.social

@KidneyWars @NephMadness I'm excited for this matchup! HDF vs Incremental dialysis @NephroSeeker @hswapnil

Thank you @_jeffreyha for the first #NephMadness topic idea! @NephMadness can we make an award for those whose suggestions end up in the tournament?

#NephMadness 2025: The PodCrawl buff.ly/p3xR3cg Featuring the following podcasts: - @thecurbsiders - Life as a Nephrology Professional @NKF_NephPros - @CuriousClinPod - #RheumMadness - @NephJC_Podcast - @LabPoison - @nephronsegment - The Kidney Chronicles

@yuzhi_xi @AmerAcadPeds @ngderekk @meg_data @suefurth_chop @funsocdoc @drjosflynn @CKiDStudy @borrelli_silvio @paolochiodini @LucaDeNicola4 @MarkCanney @ArennJauhal @ReichHeather @SeanJBarbour @GLDiTanna @ArnottClare @AmyKang23 @AgarwalRajivMD @gbakris @anythingbox70 @MarcoTrevi6 @CMClase @FuEdouard @jjcarrero1 @ChristianCombe @denisfouque1 @MauriceLaville @sophieliabeuf @pecoitsfilho @NMansencal @Benedicte55140 From the #Cardiorenal Collection: Kidney Function, Albuminuria and Risk of Incident Atrial Fibrillation: A Systematic Review & Meta-Analysis bit.ly/45AL0NK (FREE temporarily) @_jeffreyha @DearbhlaKelly4 @brendonneuen @VladoPerkovic @MinJun____ @badves

my draft pick from #KidneyWk LBCT 2023 (a poster!), has now been published in @JASN_News journals.lww.com/jasn/abstract/… Lead by Ziv Harel @UnityHealthTO and @DrRonWald See Dr Harel's presentation for us here: youtube.com/watch?v=RBU2az…

The KDIGO 2025 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD) is available for public review through Friday, November 22. You can download the public review draft and share comments via the feedback survey on the KDIGO Anemia in CKD Guideline Website: kdigo.org/guidelines/ane… KDIGO will prepare a final version for publication based on feedback received during public review. We thank you in advance for your time and insights. #anemia #CKD

Chronic kidney disease (CKD) and cardiovascular disease (CVD) are closely linked, with CKD emerging as a major CVD risk factor. Early detection and novel therapies targeting both conditions could transform patient outcomes @SradhaKotwal @VladoPerkovic ahajournals.org/doi/full/10.11…

@drmjkulkarni @NEJMEvidence @Badves @MinJun____ @hswapnil @DrDanMO @SuetoniaPalmer @DavidCWheeler2 @VladoPerkovic @georgeinstitute @UNSWMedicine @tukaramj @vskeskar @SreejithDr @divyaa24 @pradeepkj79 @raja_1980 @arvindcanchi @anupamayj @Ravindraprabh16 @drvivekkute @manirath @DivyaveerSSNeph @SayaliBThakare @kidney_boy @edgarvlermamd @WomenNeph_india @womeninnephro @isn_india @VijayKher8 @thisis_drgsp @MayuriTrivedi80 @Nephro_Sparks

@drmjkulkarni @NEJMEvidence @Badves @MinJun____ @hswapnil @DrDanMO @SuetoniaPalmer @DavidCWheeler2 @VladoPerkovic @georgeinstitute @UNSWMedicine @tukaramj @vskeskar @SreejithDr @divyaa24 @pradeepkj79 @raja_1980 @arvindcanchi @anupamayj @Ravindraprabh16 @drvivekkute @manirath @DivyaveerSSNeph @SayaliBThakare @kidney_boy @edgarvlermamd @WomenNeph_india @womeninnephro @isn_india @VijayKher8 @thisis_drgsp @MayuriTrivedi80 @Nephro_Sparks Table 1 shows drug discontinuation rates due to any cause (death, adverse events, etc.). This was 100% in both arms in DIALOGUE 3&5 (Fig S1 in our review). Note we also analyzed treatment discontinuation rates due to adverse events separately (Fig S13).

Original Article: “Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease” by @_jeffreyha et al. eviden.cc/3z2CLzM @Badves @MinJun____ @hswapnil @DrDanMO @SuetoniaPalmer @DavidCWheeler2 @VladoPerkovic @georgeinstitute @UNSWMedicine #Nephrology

@drmjkulkarni @NEJMEvidence @Badves @MinJun____ @hswapnil @DrDanMO @SuetoniaPalmer @DavidCWheeler2 @VladoPerkovic @georgeinstitute @UNSWMedicine @tukaramj @vskeskar @SreejithDr @divyaa24 @pradeepkj79 @raja_1980 @arvindcanchi @anupamayj @Ravindraprabh16 @drvivekkute @manirath @DivyaveerSSNeph @SayaliBThakare @kidney_boy @edgarvlermamd @WomenNeph_india @womeninnephro @isn_india Like with no subgroup analyses done, most meta-analyses <10 studies. Egger test to assess funnel plot asymmetry/publication bias "should be used only when ≥10 studies because when there are fewer studies power of the tests is too low to distinguish chance from real asymmetry”

@NEJMEvidence @_jeffreyha @Badves @MinJun____ @hswapnil @DrDanMO @SuetoniaPalmer @DavidCWheeler2 @VladoPerkovic @georgeinstitute @UNSWMedicine @tukaramj @vskeskar @SreejithDr @divyaa24 @pradeepkj79 @raja_1980 @arvindcanchi @anupamayj @Ravindraprabh16 @drvivekkute @manirath @DivyaveerSSNeph @SayaliBThakare @kidney_boy @edgarvlermamd 3/n Publication bias has not been reported #nephjc #NephTwitter #Nephpearls #nephrology #lastmonthinneph @WomenNeph_india @womeninnephro @isn_india

@drmjkulkarni @NEJMEvidence @Badves @MinJun____ @hswapnil @DrDanMO @SuetoniaPalmer @DavidCWheeler2 @VladoPerkovic @georgeinstitute @UNSWMedicine @tukaramj @vskeskar @SreejithDr @divyaa24 @pradeepkj79 @raja_1980 @arvindcanchi @anupamayj @Ravindraprabh16 @drvivekkute @manirath @DivyaveerSSNeph @SayaliBThakare @kidney_boy @edgarvlermamd We have also highlighted this in footnotes to Figs 3&4 in the main publication for the outcomes: CV death, stroke, composite kidney outcome & cancer-related events (Figs S5, S7, S12, & S21).

@drmjkulkarni @NEJMEvidence @Badves @MinJun____ @hswapnil @DrDanMO @SuetoniaPalmer @DavidCWheeler2 @VladoPerkovic @georgeinstitute @UNSWMedicine @tukaramj @vskeskar @SreejithDr @divyaa24 @pradeepkj79 @raja_1980 @arvindcanchi @anupamayj @Ravindraprabh16 @drvivekkute @manirath @DivyaveerSSNeph @SayaliBThakare @kidney_boy @edgarvlermamd Where no. of events wasn’t reported in ≥1 trial; generic inverse variance meta-analysis was performed. Generic inverse variance doesn’t use events data to assign study weight. Weights are calculated based on treatment effects and study size – not events data.

@drmjkulkarni @NEJMEvidence @Badves @MinJun____ @hswapnil @DrDanMO @SuetoniaPalmer @DavidCWheeler2 @VladoPerkovic @georgeinstitute @UNSWMedicine @tukaramj @vskeskar @SreejithDr @divyaa24 @pradeepkj79 @raja_1980 @arvindcanchi @anupamayj Most meta-analyses contained <10 studies. This was considered insufficient data to conduct subgroup analyses. We highlighted this as a limitation in Discussion.

@drmjkulkarni @NEJMEvidence @Badves @MinJun____ @hswapnil @DrDanMO @SuetoniaPalmer @DavidCWheeler2 @VladoPerkovic @georgeinstitute @UNSWMedicine @tukaramj @vskeskar @SreejithDr @divyaa24 @pradeepkj79 @raja_1980 @arvindcanchi @anupamayj Analyses performed separately in pts treated with dialysis & not treated with dialysis to not introduce further heterogeneity.NB despite substantial heterogeneity btw studies, still low levels of heterogeneity for primary review outcome MACE. I2<25% (low) for all comparisons Fig2

Interested in what's new in the 2024 ESC Hypertension Guidelines but don't have time to read all 107 pages? See my brief overview in @HyperAHA 👇 ahajournals.org/doi/10.1161/HY… 🔥 examples: 1) Single-pill combos for all! 2) Check for primary aldo in everyone! 3) BP goal <130/80

Due to safety concerns with erythropoiesis-stimulating agents, there is interest in developing alternative agents to treat anemia in patients with CKD. 🔬 1/3

Comprehensive review by Drs. Yeung, Toussaint & @Badves "We do not recommend routine use of vit D supplementation in (...) CKD stages 3–5, although in those with 25(OH)D deficiency there may be some rationale for replacement as benefit may outweigh harm" academic.oup.com/ckj/article/17…

@gunnar_heine @NEJMEvidence @Badves @MinJun____ @hswapnil @DrDanMO @SuetoniaPalmer @DavidCWheeler2 @VladoPerkovic @georgeinstitute @UNSWMedicine We await more longer term safety data from rigorous pharmacovigilance in the countries where HIF-PHIs are used. In low resource settings good to have an oral option to treat anemia.

@gunnar_heine @NEJMEvidence @Badves @MinJun____ @hswapnil @DrDanMO @SuetoniaPalmer @DavidCWheeler2 @VladoPerkovic @georgeinstitute @UNSWMedicine Thanks @gunnar_heine. You make a good point! Median FU in the 25 included trials was 13 months when most CV events would be accrued in high-risk patients w mod-advanced CKD. So we have robust data in terms of CV safety (even more than the EPO trials in decades past).

New in NEJM Evidence! Original Article by @_jeffreyha et al.: Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease eviden.cc/3z2CLzM @Badves @MinJun____ @hswapnil @DrDanMO @SuetoniaPalmer @DavidCWheeler2 @VladoPerkovic @georgeinstitute @UNSWMedicine